BSD Medical is Now Pyrexar Medical

The complete line of BSD Hyperthermia products are availble thru Pyrexar Medical

zjelko at umm

In an announcement this week, the University of Maryland's Proton Center has established the world's first combined Hyperthermia/Proton Beam therapy center. The therapy suite features the BSD-2000 Deep Regional Hyperthermia system as a complement to the center's 122,000 sq. ft., five bay, $270M, Varian ProBeam Proton system.

See Announcement: High-Precision Proton Therapy More Effective in Treating Certain Cancers When Combined with Thermal Therapy

Proton therapy is a precise form of radiation for the treatment of solid, localized tumors. Unlike X-ray (photon) technology, protons deliver a maximum radiation dose that stops at the tumor site. This enables our physicians to target the cancer cells with millimeter precision while sparing normal, healthy surrounding tissue in the rest of your body.

Hyperthermia, as an adjunct therapy, is expected to provide the same functionality as it would for traditional radiotherapy by increasing tumor oxygenation; boosting effective dose by 150%; preventing DNA repair to damaged cancer cells and by awakening the bodies immune system to the identify and destroy cancer.  The big difference is the belief that Hyperthermia + Proton = Carbon Ion as theorized in a paper Could hyperthermia with proton therapy mimic carbon ion therapy? by Dr. Niloy Datta.

This is an exciting advancement for hyperthermia to the forefront of cancer treatment.

 

IJOH DEC2014

BSD-2000 3D/MR Independent Quality Study

An independent quality assurance study of the five clinical BSD-2000-3D/MR systems has been published in the International Journal of Hyperthermia by H. Mulder et al.  The intent of the study was to validate the accuracy and consistency of the deep heating focus and electronic steering of this system. The study test results concluded, on these five separate systems, that “the Pyrexar Medical BSD2000-3D MR compatible applicator provides robust and reproducible heating.“ The study found that the heating characteristics were reproducible within a 95% confidence interval of 0.4˚C. Based on these evaluations, the applicator was approved for clinical use. This study further made it clear that these BSD-2000 systems provide deep selective heating focus to the center of the body equivalent phantom along with the electronic steering precision.

   • Applicator provides robust reproducible heating
   • 95% confidence interval of 0.4˚C
   • Selective heating focus with electronic steering precision
   • 5 MR-based Hyperthermia Systems already Installed

Why is this important?

1) It shows that our systems design and manufacturing is solid, even in the most sophisticated products; 2) When designing a multi-hospital, multi-country clinical study, there is hardware reliance; and 3) The research community continues to invest its time in system validation, necessary to maintain standards that industry should follow.

About the BSD-2000 3D/MR

Pyrexar Medical manufactures the most advanced hyperthermia treatment systems in the world. The model BSD-2000-3D/MR has the capability to focus radiated RF power to deep sites in the body with 3D electronic steering. A further unique advancement of this configuration is that it has been integrated with magnetic resonance imaging (MRI) which has been adapted to display non-invasive temperature change images during the elevated temperature treatments. This unique system provides image guided thermal therapy of deep tumors within the patient’s body.

This excellent quality assurance study is important to our goal of assuring high quality hyperthermia cancer treatments and to allow for results of clinical studies, at various centers around the world, to be combined in future clinical research.

Systematic quality assurance of the BSD2000-3D MR-compatible hyperthermia applicator performance using MR temperature imaging
Mulder HT1, Curto S1, Paulides MM1, Franckena M1, van Rhoon GC1
2018 Sep 11:1-9. doi: 10.1080/02656736.2018.1497209

Editors Note:  The International Journal of Hyperthermia is the official journal of STM Society of Thermal Medicine, Japanese STM and ESHO European Society for Hyperthermic Oncology.  As of June 2018, IHJ has become a full Open Access Journal.

 

We have made some updates to the Pyrexar Medical website, both in style and performance. Our goal is to promote hyperthermia as a premier adjunct cancer treatment, and to make valuable clinical data and product information readily available.

New features include:

  • A new way to explore our product features
  • An updated interactive map to find the closest available treatment centers
  • Clinical data on hyperthermia with links to abstracts
  • Clinical studies that used Pyrexar products

We hope you will take a moment and explore the website. Your feedback is important and appreciated.

Other program notes:

We will be exhibiting at this year's ASTRO in San Antonio October 21-23.  If you are planning to attend, please stop by booth #1942 and see some of our new products for 2019 on display.

wanfang site visit

Hyperthermia is reemerging on to the cancer treatment stage. There is growing acceptance of hyperthermia's role as a radiosensitizer, its effectiveness when used with chemotherapy, and maybe its most important role, in immunomodulation.

Pyrexar Medical receives requests to introduce our hyperthermia systems into new countries every month. In 2015, we were selling in 9 countries, three years later the count has grown to well over 36 countries. But the road is long from introduction to sale and is often drawn-out with regulatory filings, physician education, toward eventual acceptance. That is why we are so thankful for physicians like Dr. Gi-Ming Lai, Director of the Wan Fang Cancer Center, and his team at the Taipei Municipal Wan Fang Hospital, part of the Taipei Medical University in Taiwan.

The clinical data for hyperthermia, and specifically the BSD-2000 Deep Regional Hyperthermia system, is very impressive. But potential customers often want to see a device in a treatment environment to understand workflow and treatment planning. So when a new distributor from the region requested to visit a reference site, we reached out to our partner network and Linden Bioscience of Taiwan answered the call.

"Wan Fang is a well respected center in Taiwan, and Dr. Lai's experience with hyperthermia is unparalleled in the region" says Tainang Huang, president of Linden Bioscience. "They have a well-outfitted radiation oncology department and a strong team in medical oncology under Dr. Lai's direction".  Wan Fang was the first JCI accredited hospital in Taiwan. The 730 bed facility has more than 350 full-time physicians, and over 2000 additional staff members. Because it is affiliated with Taipei Medical University, many doctors in training from the university complete internships at Wan Fang.

We believe with solid partnerships and a willingness to share knowledge, hyperthermia will continue to grow and serve cancer patients around the globe.